Literature DB >> 22543826

Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.

Fabio Efficace1, Massimo Breccia, Susanne Saussele, Ute Kossak-Roth, Annarita Cardoni, Giovanni Caocci, Weichu Chie, Adel Naeem, Ourania Nicolatou-Galitis, Kim Cocks, Marco Vignetti, Michele Baccarani, Franco Mandelli, Mirjam Sprangers.   

Abstract

The objective of this study was to investigate the health-related quality of life (HRQOL) aspects valued the most by patients with chronic myeloid leukemia (CML) receiving targeted therapies (TT), and to compare their perception with that of health-care professionals' (HCPs). Semi-structured interviews were conducted with 137 CML patients receiving TT from five different countries. An additional sample of 99 CML patients, completing an online interview, was considered for supportive analyses. A sample of 59 HCPs from 12 countries also participated in the study. Patients and HCPs were asked to rate and rank the importance of a predefined list of 74 HRQOL aspects of potential relevance for CML patients. Patients and HCPs agreed that the following five aspects are most important: fatigue, muscle cramps, swelling, worries, and uncertainty about health condition in the future, and importance of social support in coping with the disease. However, the difference in rankings between the two groups was substantial with respect to other HRQOL aspects investigated. Patients valued some issues related to symptoms much higher than HCPs, thus suggesting that a better symptom management could be the crucial aspects to improve HRQOL of CML patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543826     DOI: 10.1007/s00277-012-1458-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  19 in total

1.  International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

Authors:  Fabio Efficace; Michele Baccarani; Massimo Breccia; Susanne Saussele; Gregory Abel; Giovanni Caocci; Francois Guilhot; Kim Cocks; Adel Naeem; Mirjam Sprangers; Simone Oerlemans; Weichu Chie; Fausto Castagnetti; Felice Bombaci; Giora Sharf; Annarita Cardoni; Lucien Noens; Stephan Pallua; Marzia Salvucci; Ourania Nicolatou-Galitis; Gianantonio Rosti; Franco Mandelli
Journal:  Qual Life Res       Date:  2013-09-13       Impact factor: 4.147

Review 2.  The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.

Authors:  Hemant S Murthy; William A Wood
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

3.  Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.

Authors:  Qian Jiang; Hai-Bo Wang; Lu Yu; Robert Peter Gale
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-01       Impact factor: 4.553

4.  Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.

Authors:  Kelly L Schoenbeck; Ehab Atallah; Li Lin; Kevin P Weinfurt; Jorge Cortes; Michael W N Deininger; Vamsi Kota; Richard A Larson; Michael J Mauro; Vivian G Oehler; Javier Pinilla-Ibarz; Jerald P Radich; Charles A Schiffer; Neil P Shah; Richard T Silver; James E Thompson; Kathryn E Flynn
Journal:  J Natl Cancer Inst       Date:  2022-01-11       Impact factor: 11.816

5.  Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.

Authors:  Fabio Efficace; Massimo Breccia; Francesco Cottone; Iris Okumura; Maribel Doro; Francesca Riccardi; Gianantonio Rosti; Michele Baccarani
Journal:  Support Care Cancer       Date:  2016-07-23       Impact factor: 3.603

6.  Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.

Authors:  Qian Jiang; Haibo Wang; Lu Yu; Robert Peter Gale
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-11       Impact factor: 4.553

7.  Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.

Authors:  Qian Jiang; Lu Yu; Robert Peter Gale
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-29       Impact factor: 4.553

8.  Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor.

Authors:  Nelson Hamerschlak; Carmino de Souza; Ana Lúcia Cornacchioni; Ricardo Pasquini; Daniel Tabak; Nelson Spector; Merula Steagall
Journal:  Support Care Cancer       Date:  2014-03-20       Impact factor: 3.603

9.  Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.

Authors:  Jorge E Cortes; Jeffrey H Lipton; Carole B Miller; Lambert Busque; Luke P Akard; Javier Pinilla-Ibarz; Christopher Keir; Ghulam Warsi; Felice P Lin; Michael J Mauro
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-02-16

10.  The impact of COVID-19 on patients with hematological malignancies: the mixed-method analysis of an Israeli national survey.

Authors:  Ilana Levy; Giora Sharf; Shlomit Norman; Tamar Tadmor
Journal:  Support Care Cancer       Date:  2021-06-14       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.